Across TCGA pan-cancer cohorts, TUBG2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TUBG2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher TUBG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TUBG2 expression acts as an unfavorable survival marker.
THYM, COAD, and LIHC are the cancer types where TUBG2 Mutation most reproducibly stratifies survival.